NNE to build Biogen's new production plant in Medicon Valley  

Construction of Biogen's USD 250 million production facility commences March 2003

Novo Nordisk Engineering (NNE) is to build Biogen's new production facility in Medicon Valley north of Copenhagen, writes national broadsheet Berlingske Tidende. The construction contract itself has been awarded to the US engineering giant Fluor with NNE as the sub-supplier. The order is NNE's largest ever outside the Novo Group and has a total value of USD 250 million. Construction will start in March 2003.


Biogen's new plant is the company's first production facility outside of the US, and will produce products for the European market as well as serving in a backup capacity for the US market. Biogen's multiple sclerosis treatment Avonex (Interferon beta 1a) will be the first product put into production. However Biogen says that the factory's principal role will be to produce two as yet unapproved drugs – Amevive for psoriasis and Antegren for Crohn's disease and multiple sclerosis.

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×